Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6975296 | 0.92 | LMNA (0.49) | ELANELMNARECQLRAD52ALDH1A1 | |
| SCHEMBL6980198 | 0.86 | ELANE (0.55) | ELANELMNARECQLRAD52ALDH1A1 | |
| SCHEMBL13075495 | 0.80 | RECQL (0.49) | ELANELMNARECQLRAD52ALDH1A1 | |
| SCHEMBL20945000 | 0.79 | NPSR1 (0.49) | ELANELMNARECQLRAD52ALDH1A1 | |
| SCHEMBL16918355 | 0.79 | KDM4E (0.46) | ALDH1A1SMN1; SMN2L3MBTL1KMT2AKDM4E | |
| SCHEMBL2868944 | 0.78 | ALDH1A1 (0.47) | LMNAALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL19172759 | 0.78 | RECQL (0.47) | ELANELMNARECQLRAD52ALDH1A1 | |
| SCHEMBL6969610 | 0.78 | RECQL (0.47) | ELANELMNARECQLRAD52ALDH1A1 | |
| SCHEMBL20945137 | 0.77 | PARP1 (0.49) | ELANEALDH1A1SMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL20945317 | 0.77 | RAD52 (0.48) | ELANELMNARECQLRAD52ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030181498-A1 | Bicyclic heteroaryl compounds as inhibitors of the interaction between the integrin alpha4beta1 receptor and vcam-1 and/or fibronectin | ASTRAZENECA AB (SE) | 2003-09-25 | — | — | US | disclosed |
| EP-1272487-A1 | BICYCLIC HETEROARYL COMPOUNDS AS INHIBITORS OF THE INTERACTION BETWEEN THE INTEGRIN ALPHA4BETA1 RECEPTOR AND VCAM-1 AND/OR FIBRONECTIN | AstraZeneca AB (SE) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001053295-A1 | BICYCLIC HETEROARYL COMPOUNDS AS INHIBITORS OF THE INTERACTION BETWEEN THE INTEGRIN ALPHA4BETA1 RECEPTOR AND VCAM-1 AND/OR FIBRONECTIN | ASTRAZENECA AB (SE) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181498-A1 | Bicyclic heteroaryl compounds as inhibitors of the interaction between the integrin alpha4beta1 receptor and vcam-1 and/or fibronectin | VCAM1, FN1, ITGA4 | ELANE 1055/4885LMNA 2210/4885RECQL 4584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.